Abstract
Aim:
To investigate the antitumor activity and safety of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand (rmh TRAIL).
Methods:
Antitumor activity of rmh TRAIL was evaluated by using several tumor cell lines by MTT assay in vitro, and by using a mouse xenograft model in vivo. rmh TRAIL-induced apoptosis in tumor cells was detected by cell death enzyme-linked immunosorbent assay (ELISA), TdT-mediated dUTP nick-end labeling (TUNEL) assay and flow cytometry. The safety of rmh TRAIL was also evaluated in several normal human cell lines.
Results:
At the concentration of 0.32–1000 ng/mL, rmh TRAIL remarkably inhibited the proliferation of 5 tumor cell lines from lung, colon, and breast cancer compared with wild type (wt TRAIL) in vitro, whereas at the concentration of 1 ng/mL-10 μg/mL, rmh TRAIL showed no or mild cytotoxicity in the normal cell lines. rmh TRAIL (3,15 mg/kg, ip, once daily for 10 d) exerted a significant inhibition on the growth of xenograft tumor NCI-H460 in nude mice compared with the saline group (P<0.01), and was more potent than wt TRAIL, a positive control. The apoptosis of NCI-H460 cells was markedly induced in a concentration-dependent and time-dependent manner after rmh TRAIL treatment. The percentage of apoptotic cells induced by rmh TRAIL in NCI-H460 cells was significantly higher than that by wt TRAIL.
Conclusion:
rmh TRAIL provided potent antitumor activity in vivo and in vitro, whereas most normal human cells were resisitant to rmh TRAIL. The results suggested that rmh TRAIL might be a useful anticancer agent in future.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Jacobson MD, Weil M, Raff MC . Programmed cell death in animal development. Cell 1997; 88: 347–54.
Steller H . Mechanisms and genes of cellular suicide. Science 1995; 267: 1445–9.
Wyllie AH . Apoptosis: cell death in tissue regulation. J Pathol 1987; 153: 313–6.
Moriya N, Miwa H, Orita K . Antitumor effects of bacterial lipopolysaccharide and tumor necrosis factor in mice. Jpn J Surg 1984; 14: 163–6.
Ishida Y, Kondo T, Tsuneyama K, Lu P, Takayasu T, Mukaida N . The pathogenic roles of tumor necrosis factor receptor p55 in acetaminophen-induced liver injury in mice. J Leukoc Biol 2004; 75: 59–67.
Lombard C, McKallip RJ, Hylemon PB, Nagarkatti PS, Nagarkatti M . Fas ligand-dependent and -independent mechanisms of toxicity induced by T cell lymphomas in lymphoid organs and in the liver. Clin Immunol 2003; 109: 144–53.
Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Jillian K, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673–82.
Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenzai A . Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687–90.
Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155–62.
Kelley SK, Harris LA, Xie D, DeForge L, Totpal K, Bussiere J, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001; 299: 31–8.
Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157–63.
Voelkel-Johnson C, King DL, Norris JS . Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin adenoviral delivery of full-length TRAIL. Cancer Gene Ther 2002; 9: 164–72.
Yoshida S, Narita T, Koshida S, Ohta S, Takeuchi Y . TRAIL/ Apo2L ligands induce apoptosis in malignant rhabdoid tumor cell lines. Pediatr Res 2003; 54: 709–17.
Bouralexis S, Findlay DM, Atkins GJ, Labrinidis A, Hay S, Evdokiou A . Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer 2003; 89: 206–14.
Frese S, Brunner T, Gugger M, Uduehi A, Schmid RA . Enhancement of Apo2L/TRAIL(tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein. J Thorac Cardiovasc Surg 2002; 123: 168–74.
Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M, et al. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-inducing apoptosis. Int J Cancer 2002; 99: 491–504.
Mariani SM, Matiba B, Armandola EA, Krammer PH . Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J Cell Biol 1997; 137: 221–9.
Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A, et al. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol 1996; 6: 750–2.
Wand WR . In vivo methods. In: Teacher BA, editor. Anticancer drug development guide, preclinical screening, clinical trials, and approval. Humana Press: Totowa NJ; 1997. p59–213.
Aragane YD, Kulms D, Metza D, Wilkes G, Poppelman B, Luger TA, et al. Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/Apo-1) independently of its ligand CD95L. J Cell Biol 1998; 140: 171–82.
Hymowitz SG, O'Connell MP, Ultsch MA, Hurst A, Totpal K, Ashkenzai A, et al. A unique zinc-binding site revealed by a high-resolution x-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 2000; 39: 633–40.
Armeanu S, Lauer UM, Smirnow I, Schenk M, Weiss TS, Gregor M, et al. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res 2003; 63: 2369–72.
Mundt B, Kuhnel F, Zender L, Paul Y, Tillmann H, Trautwein C, et al. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J 2003; 17: 94–6.
Roth W, Isenman S, Naumann U, Kugler S, Bahr M, Dichgans JA, et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 1999; 265: 479–83.
Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatocyte toxicity of recombinant Apo2L/ TRAIL versions. Nat Med 2001; 7: 383–5.
Srivastava RK . TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 2001; 3: 535–46.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by the Innovation Fund for Small Technology-based Firms (No 04C26211100286) and High Technology Research and Development Program of China (863 Program) (No 2005AA2Z3H50)
Rights and permissions
About this article
Cite this article
Fang, F., Wang, Ap. & Yang, Sf. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand. Acta Pharmacol Sin 26, 1373–1381 (2005). https://doi.org/10.1111/j.1745-7254.2005.00206.x
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1111/j.1745-7254.2005.00206.x
Keywords
This article is cited by
-
Aponermin: First Approval
Drugs (2024)
-
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial
BMC Cancer (2023)
-
Escaping cell death via TRAIL decoy receptors: a systematic review of their roles and expressions in colorectal cancer
Apoptosis (2022)
-
Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study
Cancer Chemotherapy and Pharmacology (2017)
-
Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma
Chinese Journal of Cancer (2016)
